Related Experiment Videos
[Studies on the effectiveness of a new model for treating tuberculosis with prolonged administration of isoniazid]
Abstract:
The aim of the study was to determine the therapeutical effectiveness of a new regimen in freshly diagnosed cases of pulmonary tuberculosis. In this model PZA and SM were excluded, but INH administration was prolonged. Instead of INH and RMP a combined drug was given--RIFAMAZIDE (Polfa). Therapy was carried out in three stages: I stage lasting 3 months during which Rifamazide (600 mg RMP, 300 mg INH) and EMB (25 mg per kg b.w.) was given; II stage-during which Rifamazide was given (2 tablets.) for 3 months; III stage--INH monotherapy (300 mg daily) was continued for 6 months. During the first stage all patients were hospitalized at the Institute of Tuberculosis. The second stage was carried out under supervision of an out-patient clinic. During the third stage patients received their INH at their homes. The study group consisted initially of 58 patients, of which 11 were dropped out due to primary resistance, change of therapy, non-compliance, and non-tolerance of drugs. The final evaluation was carried out basing on results from 47 patients. In all patients a negative sputum culture was achieved. In most during the first two months of therapy. All demonstrated improvement in radiological evaluation. In 38 patients the follow-up lasted 2-6 years, in the remaining nine 2 years. Recurrencies were not observed. Good acceptation by the patients of Rifamazide was found.
Insights
This study shows a new tuberculosis treatment regimen using Rifamazide is effective, achieving negative sputum cultures and radiological improvement in patients. No recurrences were observed during long-term follow-up.
Area of Science:
- Pulmonary Medicine
- Infectious Diseases
- Pharmacology
Context:
- Pulmonary tuberculosis (TB) requires effective treatment regimens.
- New drug combinations are explored to improve TB therapy outcomes.
- Rifamazide, a combination of rifampicin and isoniazid, was investigated.
Purpose:
- To evaluate the therapeutic effectiveness of a novel treatment regimen for newly diagnosed pulmonary tuberculosis.
- To assess the efficacy of Rifamazide in place of standard isoniazid and rifampicin.
- To determine the safety and patient acceptance of the new regimen.
Summary:
- A three-stage regimen was used: 3 months of Rifamazide (rifampicin 600mg, isoniazid 300mg) plus ethambutol, followed by 3 months of Rifamazide, and 6 months of isoniazid monotherapy.
- The study included 47 patients, with all achieving negative sputum cultures, mostly within two months.
- Radiological improvements were observed in all patients, with no recurrences noted during 2-6 year follow-up.
Impact:
- This new regimen demonstrated high efficacy in treating pulmonary tuberculosis.
- The study suggests Rifamazide is well-accepted by patients.
- The findings support the potential of Rifamazide as a component of TB treatment.